search
Back to results

TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE) (ACHIEVE)

Primary Purpose

Resistant Hypertension

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
PARADISE percutaneous renal denervation
Sponsored by
ReCor Medical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Resistant Hypertension focused on measuring Hypertension, Blood pressure, Renal denervation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Resistant hypertension, as defined in the 2007 ESH-ESC guidelines
  • 18 years of age or older
  • Negative pregnancy test for female patients of childbearing potential
  • Willing and able to comply with follow-up requirements
  • Signed informed consent

Exclusion Criteria:

  • Secondary hypertension
  • Main renal arteries length < 20 mm
  • Main renal arteries diameter < 4 mm
  • Renal artery stenosis
  • Iliac/femoral artery stenosis precluding insertion of the catheter
  • Untreated allergy to contrast media
  • Currently participating in the study of an investigational drug or device
  • Moderate to severe renal insufficiency

Sites / Locations

  • Universitäts-Herzzentrum Freiburg • Bad Krozingen
  • Universitätsklinikum Essen
  • CardioVasculäres Centrum
  • Asklepios Klinik St. Georg
  • Universitätsklinikum des Saarlandes
  • Universitätsklinikum Lübeck
  • Erasmus MC - Thoraxcenter
  • Sahlgrenska Universitetssjukhuset

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Percutaneous renal denervation

Arm Description

PARADISE percutaneous renal denervation

Outcomes

Primary Outcome Measures

Percentage of patients with device- or procedure-related adverse events
Anticipated adverse events include: Access site and access-related vascular injury Renal artery complications, including: stenosis, aneurysm, dissection, and perforation Renal complications, including: renal infarction, acute kidney injury, and renal failure Arterial and venous thromboembolic events, including: myocardial infarction, stroke or transient ischemic attack, pulmonary embolism, and deep vein thrombosis Systemic effects, including: allergic reaction and infection
Change from baseline in systolic blood pressure
Change from baseline in systolic blood pressure

Secondary Outcome Measures

Change from baseline in diastolic blood pressure
Change from baseline in diastolic blood pressure
Change from baseline in anti-hypertensive medication intake
Change from baseline in anti-hypertensive medication intake
Changes from baseline in pulse pressure and nocturnal dipping
Changes from baseline in pulse pressure and nocturnal dipping

Full Information

First Posted
February 8, 2013
Last Updated
July 5, 2018
Sponsor
ReCor Medical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01789918
Brief Title
TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)
Acronym
ACHIEVE
Official Title
TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Completed
Study Start Date
January 9, 2013 (Actual)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ReCor Medical, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The ACHIEVE study is a single-arm, open-label, prospective, post-market follow-up study to include up to one hundred (100) eligible patients as defined within the clinical investigational plan, with a twelve month follow-up period. The ACHIEVE study was originally designed in accordance with the 2007 ESH ESC guidelines for resistant hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Resistant Hypertension
Keywords
Hypertension, Blood pressure, Renal denervation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
96 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Percutaneous renal denervation
Arm Type
Experimental
Arm Description
PARADISE percutaneous renal denervation
Intervention Type
Device
Intervention Name(s)
PARADISE percutaneous renal denervation
Other Intervention Name(s)
ReCor Medical PARADISE
Intervention Description
Intravascular ultrasound emission
Primary Outcome Measure Information:
Title
Percentage of patients with device- or procedure-related adverse events
Description
Anticipated adverse events include: Access site and access-related vascular injury Renal artery complications, including: stenosis, aneurysm, dissection, and perforation Renal complications, including: renal infarction, acute kidney injury, and renal failure Arterial and venous thromboembolic events, including: myocardial infarction, stroke or transient ischemic attack, pulmonary embolism, and deep vein thrombosis Systemic effects, including: allergic reaction and infection
Time Frame
12 months
Title
Change from baseline in systolic blood pressure
Description
Change from baseline in systolic blood pressure
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Change from baseline in diastolic blood pressure
Description
Change from baseline in diastolic blood pressure
Time Frame
12 months
Title
Change from baseline in anti-hypertensive medication intake
Description
Change from baseline in anti-hypertensive medication intake
Time Frame
12 months
Title
Changes from baseline in pulse pressure and nocturnal dipping
Description
Changes from baseline in pulse pressure and nocturnal dipping
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
Change from baseline in EQ-5D Quality of Life score
Description
Change from baseline in EQ-5D Quality of Life score
Time Frame
12 months
Title
Change from baseline in cardiac function
Description
Change from baseline in cardiac function
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Resistant hypertension, as defined in the 2007 ESH-ESC guidelines 18 years of age or older Negative pregnancy test for female patients of childbearing potential Willing and able to comply with follow-up requirements Signed informed consent Exclusion Criteria: Secondary hypertension Main renal arteries length < 20 mm Main renal arteries diameter < 4 mm Renal artery stenosis Iliac/femoral artery stenosis precluding insertion of the catheter Untreated allergy to contrast media Currently participating in the study of an investigational drug or device Moderate to severe renal insufficiency
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thomas Zeller, Professor
Organizational Affiliation
Universitäts-Herzzentrum Freiburg • Bad Krozingen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitäts-Herzzentrum Freiburg • Bad Krozingen
City
Bad Krozingen
ZIP/Postal Code
79189
Country
Germany
Facility Name
Universitätsklinikum Essen
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
CardioVasculäres Centrum
City
Frankfurt
ZIP/Postal Code
60389
Country
Germany
Facility Name
Asklepios Klinik St. Georg
City
Hamburg
ZIP/Postal Code
20099
Country
Germany
Facility Name
Universitätsklinikum des Saarlandes
City
Homburg/Saar
ZIP/Postal Code
66424
Country
Germany
Facility Name
Universitätsklinikum Lübeck
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Erasmus MC - Thoraxcenter
City
Rotterdam
ZIP/Postal Code
3015
Country
Netherlands
Facility Name
Sahlgrenska Universitetssjukhuset
City
Göteborg
ZIP/Postal Code
413 45
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)

We'll reach out to this number within 24 hrs